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OBJECTIVES: Obesityis linked to increased mortality from many cancer types, and esophageal adenocarcinoma (EAC) displays
one of the strongest epidemiological associations. The aims of this study are to dissect molecular pathways linking obesity with
EAC and to determine if obesity is linked to increased aggressiveness of this disease.
METHODS: Affymetrix microarrays identiﬁed altered signaling pathways in an EAC cell line following coculture with visceral
adipose tissue or isolated adipocytes from viscerally obese EAC patients (n¼6). Differentially expressed genes were
subsequently investigated in patient tumor biopsies by quantitative reverse transcriptase PCR and examined with respect to
obesity status, tumor biology, and patient survival.
RESULTS: Visceral adipose tissue induced expression of genes involved in epithelial mesenchymal transition (EMT),
plasminogen activator inhibitor (PAI)-1, and transcription factor SNAI2, in an EAC cell line. In EAC patient tumor biopsies from
obese patients, we noted elevated expression of these genes, together with reduced expression of epithelial marker E-cadherin.
SNAI2 was associated with EAC prognosis.
CONCLUSIONS: Expression of EMT genes, PAI-1 and SNAI2, was elevated in tumors of obese EAC patients, and SNAI2 was
associated with poor survival. Genes deregulated in obesity and associated with prognosis may represent potential targets for
treatment stratiﬁcation of obese EAC patients.
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INTRODUCTION
Overweight and obesity are linked to increased incidence and
mortality from multiple cancer types,
1 with esophageal
adenocarcinoma (EAC) displaying one of the strongest
epidemiological associations.
2 The incidence of this aggres-
sive cancer has risen by 50% in the last 15 years,
3 mirroring
thealarmingriseinobesity,andover40%ofcasesofEACare
now estimated to be directly attributable to excess adiposity.
4
EAC is a highly lethal disease due in part to early malignant
tumor cell dissemination,
5 indicating that pathways of tumor
invasion and metastasis may be of particular importance. In
this study, we sought to investigate if these pathways are
modulated by obesity in EAC.
In addition to its role as a proteolysis inhibitor, plasminogen
activator inhibitor 1 (PAI-1) has a direct role in cell attachment
and detachment to vitronectin through competition with cell
surface integrins and uPAR for vitronectin binding sites, thus
modulating tumor cell migration.
6 Treatment of tumor cells
with exogenous PAI-1 has been found to induce a dose-
dependent decrease in vitronectin binding and a correspond-
ing increase in migratory and invasive capacity, with these
effects abrogated by an antibody against PAI-1.
7 PAI-1 is
highly induced in SNAIL, SNAI2, and E47-transfected
epithelial cells undergoing epithelial mesenchymal transition
(EMT)
8 and is the most prominently induced transcript in the
TGF-b1 and EGF-induced ‘‘scatter’’ phenotype in malignant
human keratinocytes,
9 indicating an important role for this
extracellular matrix remodeling protein in the process of EMT.
In addition, PAI-1 is a circulating adipokine, elevated in
obesity, and with a direct role in the development of insulin
resistance.
10 Inhibition of PAI-1 could therefore be particularly
relevant in viscerally obese patients with raised circulating
levels of this adipokine.
The process of EMT is required for tumor cells to acquire a
migratory phenotype via altered expression of cell adhesion
molecules and reorganization of the cytoskeleton. SNAI2 is
a well-established transcriptional regulator of this process
actingoften,butnotalways,viarepressionoftheepithelialcell
adhesion molecule E-cadherin.
11 In addition, expression of
SNAI2 in adipose tissue is required for adipogenesis, and
SNAI2-overexpressing mice display adipocyte hypertrophy,
while adipose tissue mass is reduced in SNAI2-deﬁcient
mice.
12 SNAI2 signaling thus represents a common pathway
in both adipose tissue and tumor cells, indicating its potential
as a novel therapeutic target in obesity-fuelled cancers.
The aim of this study was to investigate molecular
mechanisms underlying the association of obesity and EAC,
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www.nature.com/ctgbased on the hypothesis that adipose tissue would differen-
tially affect the expression of pro-tumor pathways in EAC
cells. Affymetrix microarray technology determined the effect
of coculturing EAC cells with adipose tissue and adipocytes,
and the expression of genes identiﬁed using this coculture
system was subsequently investigated in patient tumor
biopsies with respect to obesity status, tumor biology, and
survival. For the ﬁrst time, we report increased expression
of SNAI2 and PAI-1 in the tumors of obese EAC patients,
with SNAI2 signiﬁcantly associated with poor prognosis. The
identiﬁcation of gene expression pathways responsible for
obesity-fuelled cancers could present novel therapeutic
targets for stratiﬁed treatment of obese cancer patients.
METHODS
Patient cohort. All patients gave informed consent for
use of their tissue in this study and the study obtained
ethical approval from St James’s Hospital Ethical Review
Board (Table 1). EAC patients were separated into viscerally
obese and non-obese categories by waist circumference
(WC) according to the International Diabetes Federation
criteria,
13 by body mass index (BMI) Z30kg/m
2,o rb y
visceral fat area (VFA). There currently exists no standard
cutoff value for VFA and cancer risk. We therefore used a
VFA Z130cm
2, established as a cutoff for metabolic risk
of CVD
14,15 and previously published by our group in EAC
patients.
16
Tissue preparation. Tumor biopsies from EAC patients
were immediately taken from fresh tumor tissue following
surgical resection and processed by a designated biobank
technician, using standardized operating procedures in order
to procure consistently high-quality biospecimens, as
previously published.
17 Visceral adipose tissue specimens
were excised at the commencement of surgery and imme-
diately transported in transport buffer (phosphate-buffered
saline, glucose (0.1%), and gentamycin (0.05mg/ml)) for
processing. To generate adipose tissue-conditioned medium,
an adapted protocol from Fried and Moustaid-Moussa
18 was
used. Brieﬂy, visceral adipose tissue was minced, washed
in phosphate-buffered saline, and cultured in M199 medium
(ISIS, Wicklow, Ireland) (containing 0.05mg/ml gentamycin)
at a ratio of 5g adipose tissue to 10ml medium for 72h,
aliquotted, and stored at  801C until analyzed. Visceral
adipose tissue (10g) was digested with collagenase buffer
(2mg/ml Type II collagenase (Sigma, Wicklow, Ireland), 4%
bovine serum albumin (Sigma) in Krebs–Ringer bicarbonate
buffer, ISIS, Wicklow, Ireland, pH 7.4), and extracted
adipocytes were ceiling cultured at a dilution of 250,000
cells per well as previously described.
19
Cell culture. The OE33 cell line, derived from EAC
(ECACC, Health Protection Agency Culture Collections,
Salisbury, UK), was maintained in RPMI medium supple-
mented with penicillin (50U/ml), streptomycin (50mg/ml), and
10% fetal calf serum at 371C and 5% CO2. The OE33 cell
line was used at 70% conﬂuency and serum starved in RPMI
medium containing 0.5% fetal calf serum for a period of 16h
before each experiment. For NuGO array nugohs1a520180
microarrays and validations, OE33 cell line was seeded at
50,000 cells per well insert and cultured in a non-contact
transwell system (Corning, New York, NY, USA) containing
visceral adipose tissue, adipocytes, or control M199 medium
for a period of 24h.
Microarray analysis. RNA was extracted from tumor cell
lines using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA,
USA), according to the manufacturer’s instructions. RNA
purity was assessed and complementary DNA was
synthesized using random hexamers (Invitrogen, Carlsbad,
CA, USA). Gene expression in the OE33 cell line following
non-contact coculture with visceral adipose tissue and
adipocytes from viscerally obese EAC patients (n¼6) was
examined using NuGO array nugohs1a520180 microarrays,
custom designed by the Nutrigenomics Organisation (NuGO;
www.nugo.org) to include a number of nutrition- and obesity-
related genes. We used the ‘entrezg’ version 14.0.0 anno-
tation from the MBNI custom cdf database, reﬂecting the
latest remapping of Affymetrix probes based on current
data in the NCBI database (http://brainarray.mbni.med.
umich.edu). All RNA samples processed on Affymetrix
microarrays had an RNA integrity number 46.7 and a
260/280 ratio 41.65. Following microarray hybridization,
all arrays were assessed for quality using a set of standard
metrics (including RNA degradation), as implemented in
the AffyQCReport library in R;
20 all arrays passed quality
control checks. Arrays were then background corrected
and normalized using the GCRMA function,
21 and then
ﬁltered to remove genes in the lowest 10% of variance
using a variance ﬁlter. More detailed information on the
microarray experiments is available online via the GEO
public database (Accession ID: GSE36841).
Quantitative reverse transcriptase PCR. RNA from
original array samples and RNA from an independent
cohort of cocultured samples was used for array valida-
tions, carried out using the following primer sets with
dual labeled probes (Metabion, Munich, Germany): PAI-1
(fw: 50-GCCATGGAACAAGGATGAGATC-30, rv: 50-GCCCT
GGACCAGCTTCAGA-30, probe: 50-Fam-CCACAGACGCGA
TCTTCGTCCAGC-Tamra-30), and primer/probe sets (Applied
Biosystems, Carlsbad, CA, USA): SPP1 (Hs00959010_m1),
SNAI2 (Hs00161904_m1), and E-cadherin (Hs01023894_m1).
For gene expression analysis of tumor biopsies, RNA was
extracted from tumor biopsies using Qiagen RNeasy Mini Kit,
according to the manufacturer’s instructions and analyzed
using quantitative reverse transcriptase polymerase chain
reaction (qPCR), as above.
Statistical analysis. Analysis of alterations in gene
expression in tumor cells following coculture with adipose
tissue and correlation between clinicopathological features
and gene expression was carried out using GraphPad
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). A
P-value of o0.05 was taken as a statistically signiﬁcant
association between two variables. Affymetrix microarrays
were analyzed using predeﬁned scripts and ﬂexible pro-
gramming with the R software (www.r-project.org) environ-
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used to select signiﬁcantly altered single genes,
22 with a
signiﬁcance threshold of a¼0.05 (adjusted for multiple
testing). Single-gene changes were ranked by log-fold change
(logFC). Gene set enrichment analysis (GSEA) was used to
examine the changed pathway expression; the gsealmPerm
function from the GSEAlm library
23 was modiﬁed to test for
bidirectional enrichment in KEGG pathways.
24 The asso-
ciation of gene expression on patient survival was
determined by Kaplan–Meier survival analysis with gene
expression values divided into low- and high-expression
groups using the median. Signiﬁcance was determined using
the log-rank (Mantel–Cox) test. Cox regression multivariate
analysis was subsequently conducted using forward
likelihood ratio on SPSS (IBM, New York, NY, USA).
Variables tested on univariate analysis included gene
expression, pathological tumor and node stage, lymphatic
and hematological dissemination, and tumor differentiation.
Variables with a signiﬁcance level of o0.1 were included in
the multivariate model; these were gene expression, path-
ological tumor and node stage.
Results
Coculture with adipose tissue alters the expression
of pro-tumor pathways in an EAC cell line. Differential
gene regulation in OE33 cells following coculture with
visceral adipose tissue, adipocytes, or control medium
was investigated using the NuGO array nugohs1a520180
microarray. Principle component analysis and hierarchical
clustering both showed that OE33 cocultured with adipose
tissue (n¼6) segregated together, separately from OE33
cocultured with adipocytes (n¼6) and with control medium
(n¼4), according to gene expression proﬁle (Figure 1).
OE33 cocultured with adipocytes and control medium
clustered together, demonstrating that adipocyte coculture
had little transcriptomic effect on OE33 cells, in comparison
with coculture with whole adipose tissue. Indeed, there were
no signiﬁcant gene alterations in OE33 cells following
coculture with adipocytes, indicating that global alterations
in gene expression are predominantly mediated not by
adipocytes but by secreted factors from the adipose tissue
stromal vascular fraction. Pathway analysis showed cytokine
signaling, focal adhesion/EMT, and glycolysis to be the top
three signiﬁcantly upregulated pathways in OE33 following
coculture with adipose tissue, compared with coculture with
control medium (adjusted Po0.05) (Table 2). The top 10
differentially expressed genes (with adjusted Po0.1) in each
pathway were subsequently ranked by logFC; 9 belonging to
the glycolysis pathway were listed, as only this number of
genes were altered (adjusted Po0.1). There was a total of
ﬁve genes with a logFC 42; two belonged to cytokine
signaling pathways (CXCL5 and PPBP), and three belonged
to focal adhesion/EMT pathways (SPP1, PAI-1, and SNAI2)
(Table 2). We subsequently investigated altered expression
of these latter three genes, established to have direct and
important roles in focal adhesion, EMT, and tumor dissemi-
nation, in order to elucidate the relationship between obesity
and increased cancer mortality. Integrin-binding signaling
molecule, secreted phosphoprotein 1 (SPP1), underwent a
4.9 log-fold change (adjusted Po0.04), EMT transcription
factor, SNAI2, underwent a 2.5 log-fold change (adjusted
Po0.01) while marker of tumor invasion and metastasis,
PAI-1, underwent a 2.9 log-fold change (adjusted Po0.07).
Gene expression alterations of these transcripts, in addition
to laminin-5 subunits, LAMC2 and LAMB3, and integrin
subunit a3( ITGA3), were measured by qPCR, in both the
training cohort (n¼6) and in a larger, independent cohort
(n¼12), which conﬁrmed the ﬁndings of the microarray (see
Supplementary Figure 1 online).
Coculture with adipose tissue induces gene expression
of PAI-1 and SNAI2 in EAC cell lines. Early tumor dissemi-
nation is a characteristic hallmark of EAC, contributing to the
dismal ﬁve-year survival of this aggressive disease. Path-
ways in tumor invasion and metastasis could therefore
present ideal targets for therapeutic intervention. Investiga-
tion in a separate cohort (n¼12) using qPCR demonstrated
that coculture with adipose tissue induced gene expression
of SPP1 by almost 2,000 fold (Po0.02), PAI-1 by 10 fold
(Po0.0001), and the expression of SNAI2 by over 7 fold
(Po0.004) (Figure 2). In order to establish if increased
expression of these genes was associated with transition from
the epithelial to mesenchymal phenotype, we measured the
expression of epithelial cell marker, E-cadherin. We found that
coculture with adipose tissue did not alter the expression of
SNAI2 target, E-cadherin, in OE33 cells (Figure 2).
Tumor gene expression of members of the EMT path-
way, PAI-1 and SNAI2, are increased with obesity,
while expression of epithelial cell marker, E-cadherin,
is decreased. In order to assess whether tumor EMT is
affected by the presence of excess adipose tissue in vivo,
Table 1 Patient demographics
Training cohort Validation cohort Patient cohort
No. of patients 6 12 39
Sex (male), n (%) 6 (100) 10 (83.3) 39 (100)
Age at surgery, mean (range) 58.2 (49–63) 60.2 (55–69) 64 (48–81)
Diagnosis EAC EAC EAC
BMI (kg/m
2), mean (range) 30.3 (25.4–39) 30 (22–39) 26 (19–39)
WC (cm), mean (range) 107.3 (98–130) 103.8 (81–130) 95.5 (77–130)
VFA (cm
2), mean (range) 209.9 (120.9–297.6) 206 (42.5–383.8) 154 (13–384)
Metabolic syndrome, n (%) 2 (33.3) 7 (58.3) 13 (33.3)
Neoadjuvant therapy, n (%) 3 (50) 6 (50) 16 (41)
BMI, body mass index; VFA, visceral fat area; WC, waist circumference.
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E-cadherin in tumors of obese and non-obese EAC
patients. Gene expression of SPP1 was not associated
with VFA (Po0.7), WC (Po0.9), or BMI (Po0.5), and was
therefore dropped from further analysis (data not shown).
When patients were grouped by VFA, gene expression
Figure 1 Clustering heatmap analysis of genes differentially expressed in esophageal adenocarcinoma (EAC) cells following coculture with whole adipose tissue,
adipocytes, or control medium in the highest 5% of variance identiﬁed by Affymetrix microarray analysis. Numbers represent patient number, w¼OE33 following coculture
with whole adipose tissue, a¼OE33 following coculture with adipocytes, and c¼OE33 following coculture with control M199 medium.
Table 2 Top differentially expressed genes (ranked by logFC) in top three signiﬁcantly upregulated pathways in esophageal adenocarcinoma OE33 following
coculture with adipose tissue from viscerally obese EAC patients
Pathway LogFC Gene Description
Cytokine signaling* 6.941 CXCL5*** Chemokine (C–X–C motif) ligand 5
4.370 PPBP Pro-platelet basic protein (chemokine (C–X–C motif) ligand 7)
1.871 OSMR** Oncostatin M receptor
1.580 SOCS3* Suppressor of cytokine signaling 3
1.501 IL1B* Interleukin 1, beta
1.082 CCL7* Chemokine (C–C motif) ligand 7
0.873 IL4R** Interleukin 4 receptor
0.840 IL1R1 Interleukin 1 receptor, type I
0.424 IL7R* Interleukin 7 receptor
0.351 STAT5A Signal transducer and activator of transcription 5A
Focal adhesion/EMT* 4.919 SPP1* Secreted phosphoprotein 1
2.867 SERPINE1 Serpin peptidase inhibitor E1 (plasminogen activator inhibitor-1)
2.496 SNAI2* Snail homolog 2
1.353 LAMB3* Laminin, beta 3
1.255 ITGA3** Integrin, alpha 3
1.149 LAMC2* Laminin, gamma 2
0.656 SERPINB6* Serpin peptidase inhibitor, B6
0.504 ITGA6* Integrin, alpha 6
0.410 LAMC1 Laminin, gamma 1
0.269 PXN Paxillin
Glycolysis* 1.555 PDK4* Pyruvate dehydrogenase kinase, isozyme 4
1.406 ALDOC Aldolase C, fructose-bisphosphate
1.110 PFKFB3* 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
1.071 HK1** Hexokinase 1
1.036 PDK1* Pyruvate dehydrogenase kinase, isozyme 1
0.716 PFKP* Phosphofructokinase, platelet
0.697 PKM2* Pyruvate kinase, muscle
0.589 LDHC Lactate dehydrogenase C
0.350 ALDOA Aldolase A, fructose-bisphosphate
EMT, epithelial mesenchymal transition.
Genes differentially expressed between OE33 following coculture with adipose tissue or control M199 medium (*Po0.05, **Po0.01, ***Po0.0001).
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Clinical and Translational Gastroenterologyof PAI-1 was increased ﬁvefold (Po0.05) in tumors from
obese (n¼26) relative to non-obese (n¼13) EAC patients
(Table 3). This signiﬁcant effect was also observed when
patients were grouped by WC (Po0.05) and by BMI
(Po0.01). Gene expression of EMT transcription factor,
SNAI2, was increased twofold in tumor biopsies from obese
relative to non-obese EAC patients. This trend approached
statistical signiﬁcance when patients were grouped by BMI
(Po0.07), but not when patients were grouped by measures
of visceral obesity, WC (Po0.4), and VFA (Po0.3) (Table 3),
indicating that elevated SNAI2 expression is associated with
overall obesity rather than with visceral adiposity. Gene
expression of SNAI2 target, E-cadherin, was decreased
almost twofold in tumor biopsies from obese relative to non-
obese EAC patients. This association reached statistical
signiﬁcance when patients were grouped by WC (Po0.05)
and approached signiﬁcance when patients were grouped by
VFA (Po0.07) (Table 3). However, there was no association
when patients were grouped by BMI (Po0.3), indicating that,
in contrast to SNAI2, E-cadherin expression is associated
with visceral obesity rather than overall adiposity. There was
no association between elevated SNAI2 expression and
reduced E-cadherin expression on pathological tumor or node
stage, tumor differentiation, or measures of tumor dissemi-
nation. Neither was there any signiﬁcant association between
increased PAI-1 expression and these markers of aggressive
tumor biology; however, a pathologically advanced T stage
was accompanied by a twofold increase in PAI-1 expression
(Po0.17) (Table 3). As PAI-1 is elevated in obesity, this
trend indicates a potential molecular mechanism by which
excess adiposity may be associated with advanced tumor
stage.
Elevated PAI-1 and SNAI2 expression is associated with
poor patient prognosis. EAC is an aggressive disease
associated with high patient mortality due to early malig-
nant tumor dissemination.
5 In addition, there is evidence to
suggest that obesity is linked to increased cancer mortality.
1
It is therefore of great interest that the gene expression
of markers of EMT, SNAI2, E-cadherin, and PAI-1, was
found to be altered in obese EAC patients. Furthermore,
using the log-rank (Mantel–Cox) test, we found that elevated
SNAI2 expression was negatively associated with patient
survival (Po0.05), identifying this transcriptional regulator of
EMT as an obesity-associated prognostic indicator in EAC
(Figure 3). Using Cox regression multivariate analysis,
we found that SNAI2 approached signiﬁcance as an inde-
pendent prognostic indicator, after adjustment for potential
confounders (Hazard ratio: 0.221 (95% CI: 0.047–1.045),
P¼0.057). Notably, SNAI2 expression was more strongly
associated with EAC survival than established prognostic
indicators pathological tumor and node stage (P¼0.38,
P¼0.128, respectively), indicating that our sample size is
insufﬁcient to detect a signiﬁcant association with survival
using the Cox regression multivariate analysis method.
Elevated tumor levels of these genes in obesity may
represent a molecular pathway by which excess adiposity
could negatively impact on EAC prognosis. In contrast,
decreased expression of SNAI2 target, E-cadherin, showed
no association with patient survival. As SNAI2 is an impor-
tant transcriptional repressor and negative regulator of
E-cadherin, a combined survival analysis investigating high
SNAI2 with low E-cadherin was subsequently conducted.
Figure 2 Coculture of esophageal adenocarcinoma OE33with visceraladipose
tissue induces expression of genes involved in epithelial mesenchymal transition,
PAI-1 and SNAI2. Statistical analysis was performed using paired Student’s t-test
(**Po0.01, ***Po0.001 between control and whole adipose tissue treatment
groups).
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Clinical and Translational GastroenterologyTable 3 PAI-1, SNAI2, and E-cadherin expression in esophageal adenocarcinoma patients with respect to obesity status and tumor differentiation
PAI-1 expression,
mean (s.e.m.)
P SNAI2 expression,
mean (s.e.m.)
P E-cadherin expression,
mean (s.e.m.)
P
BMI (kg/m
2) 0.009 0.0693 0.2218
Non-obese o30 1.014 (0.299) 25.623 (3.549) 4.546 (0.847)
Obese Z30 3.691 (1.195) 61.411 (24.515) 3.01 (0.656)
WC (cm) 0.0397 0.3097 0.0447
Non-obese o 94cm 0.74 (0.164) 26.659 (4.976) 5.423 (1.232)
Obese Z94cm 2.833 (0.808) 46.731 (2.533) 2.999 (0.468)
VFA (cm
2) 0.031 0.2437 0.0602
Non-obese o130cm
2 0.529 (0.149) 23.839 (4.134) 5.49 (1.415)
Obese Z130cm
2 2.775 (0.74) 46.655 (14.145) 3.155 (0.442)
Tumor diff. 0.2782 0.2809 0.5852
Well/moderate 1.517 (0.492) 73.584 (26.049) 4.413 (0.639)
Poor 2.467 (0.727) 43.901 (9.297) 3.817 (0.865)
PT 0.1632 0.1796 0.4062
T0–T1 1.569 (0.671) 95.248 (49.316) 3.158 (0.803)
T2–T3 2.634 (0.748) 48.598 (12.171) 4.301 (0.656)
PN 0.5241 0.7256 0.2184
N0 1.569 (0.671) 64.717 (28.545) 3.168 (0.569)
N1 2.166 (0.557) 54.382 (15.01) 4.581 (0.792)
Lymph inv. 0.3262 0.5117 0.6864
Yes 2.26 (0.606) 55.127 (15.53) 3.90 (0.581)
No 1.504 (0.561) 77.695 (37.67) 4.45 (1.566)
Venous inv. 0.4164 0.4169 0.8639
Yes 2.299 (0.606) 48.616 (15.974) 3.963 (0.569)
No 1.504 (0.561) 72.395 (26.047) 4.161 (1.103)
Perineural inv. 0.6496 0.4895 0.3857
Yes 2.338 (0.985) 44.257 (13.09) 4.195 (0.949)
No 1.9 (0.466) 66.371 (20.284) 3.403 (0.433)
BMI, body mass index; lymph inv., lymph involvement; perineural inv., perineural involvement, expression relative to a calibrator sample (non-obese patient);
pN,pathologicalnodestage; pT,pathological tumorstage; tumordiff.,tumordifferentiation status;venousinv., venousinvolvement;VFA,visceral fatarea; WC,waist
circumference.
Figure 3 Elevated tumor gene expression of SNAI2 is associated with poor patient prognosis. Gene expression was separated into above (n¼22) and below (n¼23)
the median expression value, and Kaplan–Meier survival analysis was performed. Statistical analysis was performed using the log-rank (Mantel–Cox) test (*Po0.05).
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there was some separation between survival curves
following 1 year indicating that it may be worthwhile to
reanalyze these data after a longer follow-up period
(Figure 3). Alternatively, the mechanism of action of SNAI2
in EAC may be independent of E-cadherin repression; we
found no correlation between the expression of transcrip-
tional repressor, SNAI2, and expression of its target cell
adhesion molecule and epithelial marker, E-cadherin
(r
2¼0.024, P¼0.37).
DISCUSSION
Esophageal adenocarcinoma (EAC) has one of the strongest
epidemiological associations with obesity,
2 although mechan-
isms remain largely unknown. In this study, we hypothesized
that adipose tissue would differentially affect the expression
of pro-tumor pathways in EAC cells. To investigate this
hypothesis, we used an ex vivo explant model to identify
altered pathways in EAC cells following coculture with
adipose tissue or isolated adipocytes from matched obese
EAC patients, relative to control medium. We found that
coculture with adipose tissue induced the most pronounced
gene alterations in EAC cells, implying that the stromal
vascular fraction, comprising a range of cell subsets including
endothelial and immune cells, is the primary mediator of this
pro-tumor effect.
Using Affymetrix microarrays, we identiﬁed glycolysis,
cytokine signaling, and focal adhesion/EMT to be the top
upregulated pathways in EAC cells following coculture with
adipose tissue explants, implicating these pathways in
obesity-associated cancer. The reliance of tumor cells on
glycolysis even in aerobic conditions is termed the ‘‘Warburg
effect’’, a fundamental hallmark of cancer associated with
aggressive disease and poor prognosis,
25,26 and adipose
tissue-mediated induction of this pathway in tumor cells
indicates a mechanism by which obesity promotes cancer
mortality. Chronic, low-grade inﬂammation, a characteristic
featureofbothobesity
27andcancer,
28mayhaveanimportant
role in their epidemiological association. Circulating levels
of CXCL5 and IL-1b are elevated in obesity, and exert pro-
inﬂammatory effects linked to the development of insulin
resistance and associated pathologies.
29,30 Upregulation of
these cytokines in tumor cells by adipose tissue, combined
with upregulation of cytokine receptors, oncostatin M recep-
tor, IL-1R, IL-7R, and IL-4R, highlights a mechanism whereby
obesity could support pro-inﬂammatory signaling pathways in
cancer. Finally, with tumor metastasis accounting for the
majority of cancer-related deaths, and signaling through
the focal adhesion pathway necessary for cells to acquire a
motile, mesenchymal-like phenotype via the process of
EMT,
31 the induction of these pathways in tumor cells by
adipose tissue is of profound interest for the elucidation
of mechanisms underpinning obesity-associated cancer
mortality. We observed a sevenfold increase in expres-
sion of EMT transcriptional regulator, SNAI2, together with
a 10-fold increase in the expression of PAI-1, leading us to
examine the differential expression of these genes in EAC
patients.
Gene expression of PAI-1 was signiﬁcantly elevated
ﬁvefold in the tumors of obese EAC patients, suggesting
a function for this gene in obesity-fuelled cancer. PAI-1 has
a role in tumor cell adhesion, and TGF-b-induced PAI-1
expression in OE33 has been demonstrated to correlate with
an invasive cell phenotype in vitro.
32 Furthermore, PAI-1 is a
circulatingadipokine,whichiselevatedinobesity,andhigh-fat
diet-induced obese mice deﬁcient in PAI-1 have reduced
adipose tissue mass and increased insulin sensitivity,
33
supporting a potential role for modulation of levels of PAI-1
activity in the treatment of obesity and its comorbidities. We
found that PAI-1 tumor gene expression was elevated in
patients with more advanced pathological tumor stage,
suggesting a mechanism by which PAI-1 is associated with
poor prognosis in breast,
34,35 gastric,
36 rectal,
37,38 and color-
ectal carcinoma.
39
There is preliminary evidence that SNAI2, implicated in
malignant tumor dissemination via initiation of EMT,
11 may
partially exert its functional effect via upregulation of PAI-1
expression, and this has been demonstrated in canine
epithelial cells.
8 SNAI2 overexpression is associated with
poor prognosis in breast,
40,41 esophageal squamous cell,
42
and colorectal carcinoma,
43 and we have demonstrated it to
be a prognostic indicator in EAC. In addition, this study found
that gene expression of SNAI2 was increased twofold, while
gene expression of its target, E-cadherin, was decreased
twofold, in the tumors of obese EAC patients, implying a role
for EMT in obesity-fuelled cancer. Indeed, it has been shown
in vitro that overexpression of SNAI2 repressed E-cadherin
and induced expression of mesenchymal markers vimentin
and ﬁbronectin in the OE33 EAC cell line,
44 and that these
expression alterations corresponded to a gain in tumor cell
proliferation and invasion.
45 Interestingly, coculture with
adipose tissue-conditioned medium signiﬁcantly enhanced
EAC cell proliferative, migratory, and invasive capacity
in vitro,
46 indicating the functional effect of these adipose
tissue-induced gene alterations. Increased SNAI2 expres-
sion, together with nuclear localization of this trans-
cription factor, has been observed in EAC relative to
Barrett’s esophagus,
44 indicating the signiﬁcance of SNAI2
and the process of EMT in the malignant progression of
this disease, as well as in EAC tumor invasiveness. SNAI2
overexpression is not always associated with E-cadherin
repression, and this has been demonstrated in breast
40,41
and esophageal squamous cell carcinoma.
47 We report that
geneexpressionlevelsofE-cadherinwerenotassociatedwith
prognosis, indicating that E-cadherin-independent pathways
may be important in SNAI2-mediated pathogenesis in EAC.
In summary, we have demonstrated a novel association of
PAI-1 and SNAI2 with obesity and of SNAI2 with prognosis in
EAC, highlighting a potential mechanism by which excess
adiposity may promote malignant tumor dissemination and
contribute to the poor prognosis characteristic of this
aggressive disease. Although not yet in clinical trials, small
molecule PAI-1 inhibitors are being developed as anti-
thrombotic agents and are currently under investigation
in animal models of pulmonary ﬁbrosis;
48 this study indicates
that it would be of interest to examine the effect of these PAI-1
inhibitors in the context of obesity-fuelled cancer. In conclu-
sion, this work has identiﬁed PAI-1 and SNAI2 as additional
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targeting pathways of tumor dissemination in EAC, with the
ultimate goal of stratiﬁed treatment of obese EAC patients.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
|Esophageal adenocarcinoma (EAC) is a lethal
disease, increasing in prevalence.
|There is a strong epidemiological association
between obesity and EAC, with over 40% of cases
linked to excess adiposity.
|Molecular mechanisms underlying this association
are largely unknown.
WHAT IS NEW HERE
|Visceral adipose tissue upregulates pro-tumor
pathways in EAC.
|Expression of epithelial mesenchymal transition
promoters, PAI-1 and SNAI2, is elevated in tumors
of viscerally obese EAC patients.
|Elevated tumor SNAI2 expression is associated with
poor survival, indicating a potential mechanism
whereby obesity may contribute to increased mortality.
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